C4 Therapeutics (CCCC) reported second-quarter 2026 revenue of $6.6 million, compared with $6.5 million a year earlier. The company posted a net loss of $23.6 million, or $0.18 per share, compared with a net loss of $26.0 million, or $0.37 per share, in the second quarter of 2025.
C4 Therapeutics said cemsidomide clinical programs remain on track, including the Phase 2 MOMENTUM trial and a Phase 1b trial with elranatamab. The company reported $300.4 million in cash, cash equivalents and marketable securities as of June 30, 2026, and said it expects its current cash position to fund operations to the end of 2028.
- Second-quarter revenue was $6.6 million, up from $6.5 million in the prior-year period.
- Net loss narrowed to $23.6 million from $26.0 million a year earlier.
- Net loss per share was $0.18, compared with $0.37 in the second quarter of 2025.
- C4T received a $20 million upfront payment from Roche in May 2026 under a degrader-antibody conjugate collaboration.
- The company raised approximately $33.5 million in net proceeds through its at-the-market program during the quarter.
- Initial investigator-assessed overall response rate data from the Phase 2 MOMENTUM trial are expected in the second half of 2027.
$CCCC Hedge Fund Activity
We have seen 75 institutional investors add shares of $CCCC stock to their portfolio, and 42 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- POINT72 ASSET MANAGEMENT, L.P. removed 9,270,232 shares (-98.2%) from their portfolio in Q1 2026, for an estimated $24,380,710
- BLACKROCK, INC. added 5,848,192 shares (+285.5%) to their portfolio in Q2 2026, for an estimated $27,311,056
- SQUADRON CAPITAL MANAGEMENT LLC added 2,250,000 shares (+inf%) to their portfolio in Q1 2026, for an estimated $5,917,500
- CITADEL ADVISORS LLC added 2,063,207 shares (+460.7%) to their portfolio in Q1 2026, for an estimated $5,426,234
- STATE STREET CORP added 1,732,648 shares (+452.4%) to their portfolio in Q2 2026, for an estimated $8,091,466
- TWO SIGMA INVESTMENTS, LP added 1,526,031 shares (+101.1%) to their portfolio in Q1 2026, for an estimated $4,013,461
- GOLDMAN SACHS GROUP INC added 1,298,358 shares (+119.2%) to their portfolio in Q1 2026, for an estimated $3,414,681
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
